1446971-41-0

1446971-41-0 structure
1446971-41-0 structure
  • Name: ZLc-002
  • Chemical Name: ZLc-002
  • CAS Number: 1446971-41-0
  • Molecular Formula: C10H17NO5
  • Molecular Weight: 231.25
  • Catalog: Research Areas Neurological Disease
  • Create Date: 2022-09-13 13:05:09
  • Modify Date: 2025-08-25 19:06:39
  • ZLc-002 is a selective small-molecule inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation[1][2][3].

Name ZLc-002
Description ZLc-002 is a selective small-molecule inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation[1][2][3].
Related Catalog
In Vitro ZLc-002 (1 μM; 24 h) inhibits nNOS-CAPON in cultured hippocampal neurons from ICR mice[3]. Cell Viability Assay[3] Cell Line: ICR mice hppocampal neurons Concentration: 1 μM Incubation Time: 24 h Result: Inhibited the nNOS-CAPON in cultured hippocampal neurons from ICR mice.
In Vivo ZLc-002 (30 mg/kg; i.p. from 4-10 days until 46 days after stroke everyday) improves motor function in tMCAO mice[1]. ZLc-002 (40 mg/kg; i.v. once per day for seven days) can improve chronic mild stress (CMS)- induced anxiety-related behaviours[2]. ZLc-002 (10 μM 1 μL; hippocampus injection once per day for seven days) can improve corticosterone (CORT)-induced anxiety-related behaviours[2]. Animal Model: tMCAO mice[2] Dosage: 30 mg/kg Administration: Intraperitoneal injection; 30 mg/kg per day; from 4–10 days until 46 days after stroke Result: Signally ameliorated sroke-induced impairment of motor function and recovered from stroke in the delayed phase. Animal Model: Adult male ICR mice with CMS exposure[2] Dosage: 40 mg/kg Administration: Intravenous injection; 40 mg/kg once per day; from 21-27 days of CMS exposure for 7 days Result: Showed a therapeutic effect in CMS-induced anxiety disorder. Animal Model: Adult male ICR mice with CORT[2] Dosage: 10 μM 1 μL Administration: Hippocampus injection; 10 μM 1 μL once per day; from 21-27 days of CORT reatmentfor 7 days Result: Showed a therapeutic effect in chronic stress-induced anxiety disorders.
References

[1]. Ni HY, et al.Dissociating nNOS (Neuronal NO Synthase)-CAPON (Carboxy-Terminal Postsynaptic Density-95/Discs Large/Zona Occludens-1 Ligand of nNOS) Interaction Promotes Functional Recovery After Stroke via Enhanced Structural Neuroplasticity. Stroke. 2019 Mar;50(3):728-737.

[2]. Zhu LJ, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020 Aug;177(16):3674-3690.

[3]. Zhu LJ, et al.CAPON-nNOS coupling can serve as a target for developing new anxiolytics. Nat Med. 2014 Sep;20(9):1050-4. doi: 10.1038/nm.3644. Epub 2014 Aug 17.

Molecular Formula C10H17NO5
Molecular Weight 231.25
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.